Trevali Reports 2017 Annual Financial Results
Mar 13, 2018 20:01 pm UTC| Business
EBITDA(1) of $101 million on net revenues of $330.5 million;Cash position of $97.3 million and working capital of $144 million;Net profit of $20.2-million or $0.03 per share;Adjusted EBITDA(1) (5) (6) of $162 million and...
Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes
Mar 13, 2018 20:01 pm UTC| Business
ROCKVILLE, Md., March 13, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the “Company”), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous...
Sientra Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 13, 2018 20:01 pm UTC| Business
Remains on Track for Full and Final FDA Approval for U.S. Manufactured Implants Received ISO 13485 Certification for Breast Implants and Tissue Expanders Advanced miraDry Integration and Optimization Strategy SANTA...
Vermillion Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Mar 13, 2018 20:01 pm UTC| Business
Conference Call at 4:30 p.m. ET Today AUSTIN, Texas, March 13, 2018 -- Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the...
Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
Mar 13, 2018 20:01 pm UTC| Business
- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12- On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, March 13, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a...
Mar 13, 2018 20:01 pm UTC| Business
LONDON and CARLSBAD, Calif., March 13, 2018 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
Mar 13, 2018 20:01 pm UTC| Business
Recruitment completed in European BP-004 registration trial of BPX-501 and rimiducid Positive BPX-501 interim results reported in AML and primary immunodeficiencies GoCAR-T candidate BPX-601...